Drug Trial Radar · NCT03993392
SUBLOCADE Rapid Initiation Study
Last checked: Nov 20, 2026Latest source record: Mar 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Aug 29, 2019
Primary completion
Dec 26, 2019
Study completion Dec 26, 2019
Sponsor
- Lead sponsor
- Indivior Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 20, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the safety and tolerability of initiating SUBLOCADE™ treatment following a shorter period of transmucosal (TM) buprenorphine treatment.
Conditions
- Opioid-use Disorder
Interventions
TM buprenorphineDrug
4mg TM buprenorphine, investigator choice as to brand
SUBLOCADEDrug
300mg subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants Who Experienced Any Precipitated Withdrawal Within One Hour After SUBLOCADE AdministrationTime frame: Day 1: Pre-SUBLOCADE evaluation taken after TM buprenorphine treatment and prior to injection: SUBLOCADE evaluation taken within one hour of SUBLOCADE injection
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hassman Research Institute
Berlin, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.